OBJECTIVE: To use fluorescence in situ hybridization (FISH) to visualize genetic abnormalities in interphase cell nuclei (interphase FISH) of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas. PATIENTS AND METHODS: Between April 4, 2007, and December 4, 2008, interphase FISH was used to study paraffin-embedded preparations of tissue obtained from 18 patients listed in the Mayo Clinic Biospecimen Resource for Pancreas Research with a confirmed diagnosis of acinar cell carcinoma, ductal adenocarcinoma, islet cell carcinoma, or pancreas without evidence of neoplasia. FISH probes were used for chromosome loci of APC (see glossary at end of article for expansion of all gene symbols), BRCA2, CTNNB1, EGFR, ERBB2, CDKN2A, TP53, TYMP, and TYMS. These FISH probes were used with control probes to distinguish among various kinds of chromosome abnormalities of number and structure. RESULTS: FISH abnormalities were observed in 12 (80%) of 15 patients with pancreatic cancer: 5 of 5 patients with acinar cell carcinoma, 5 of 5 patients with ductal adenocarcinoma, and 2 (40%) of 5 patients with islet cell carcinoma. All 3 specimens of pancreatic tissue without neoplasia had normal FISH results. Gains of CTNNB1 due to trisomy 3 occurred in each tumor with acinar cell carcinoma but in none of the other tumors in this study. FISH abnormalities of all other cancer genes studied were observed in all forms of pancreatic tumors in this investigation. CONCLUSION: FISH abnormalities of CTNNB1 due to trisomy 3 were observed only in acinar cell carcinoma. FISH abnormalities of genes implicated in familial cancer, tumor progression, and the 5-fluorouracil pathway were common but were not associated with specific types of pancreatic cancer.
OBJECTIVE: To use fluorescence in situ hybridization (FISH) to visualize genetic abnormalities in interphase cell nuclei (interphase FISH) of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas. PATIENTS AND METHODS: Between April 4, 2007, and December 4, 2008, interphase FISH was used to study paraffin-embedded preparations of tissue obtained from 18 patients listed in the Mayo Clinic Biospecimen Resource for Pancreas Research with a confirmed diagnosis of acinar cell carcinoma, ductal adenocarcinoma, islet cell carcinoma, or pancreas without evidence of neoplasia. FISH probes were used for chromosome loci of APC (see glossary at end of article for expansion of all gene symbols), BRCA2, CTNNB1, EGFR, ERBB2, CDKN2A, TP53, TYMP, and TYMS. These FISH probes were used with control probes to distinguish among various kinds of chromosome abnormalities of number and structure. RESULTS:FISH abnormalities were observed in 12 (80%) of 15 patients with pancreatic cancer: 5 of 5 patients with acinar cell carcinoma, 5 of 5 patients with ductal adenocarcinoma, and 2 (40%) of 5 patients with islet cell carcinoma. All 3 specimens of pancreatic tissue without neoplasia had normal FISH results. Gains of CTNNB1 due to trisomy 3 occurred in each tumor with acinar cell carcinoma but in none of the other tumors in this study. FISH abnormalities of all other cancer genes studied were observed in all forms of pancreatic tumors in this investigation. CONCLUSION:FISH abnormalities of CTNNB1 due to trisomy 3 were observed only in acinar cell carcinoma. FISH abnormalities of genes implicated in familial cancer, tumor progression, and the 5-fluorouracil pathway were common but were not associated with specific types of pancreatic cancer.
Authors: Rebecca F McClure; Ellen D Remstein; William R Macon; Gordon W Dewald; Thomas M Habermann; Antje Hoering; Paul J Kurtin Journal: Am J Surg Pathol Date: 2005-12 Impact factor: 6.394
Authors: Megan Dann Fesinmeyer; Melissa A Austin; Christopher I Li; Anneclaire J De Roos; Deborah J Bowen Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-07 Impact factor: 4.254
Authors: Dengfeng Cao; Anirban Maitra; Jorge-Albores Saavedra; David S Klimstra; N Volkan Adsay; Ralph H Hruban Journal: Mod Pathol Date: 2005-06 Impact factor: 7.842
Authors: Gloria M Petersen; Mariza de Andrade; Michael Goggins; Ralph H Hruban; Melissa Bondy; Jeannette F Korczak; Steven Gallinger; Henry T Lynch; Sapna Syngal; Kari G Rabe; Daniela Seminara; Alison P Klein Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-04 Impact factor: 4.254
Authors: Karlheinz Holzmann; Holger Kohlhammer; Carsten Schwaenen; Swen Wessendorf; Hans A Kestler; Alexandra Schwoerer; Bettina Rau; Bernd Radlwimmer; Hartmut Döhner; Peter Lichter; Thomas Gress; Martin Bentz Journal: Cancer Res Date: 2004-07-01 Impact factor: 12.701
Authors: Emily G Barr Fritcher; Benjamin R Kipp; Jeffrey M Slezak; Laura E Moreno-Luna; Gregory J Gores; Michael J Levy; Lewis R Roberts; Kevin C Halling; Thomas J Sebo Journal: Am J Clin Pathol Date: 2007-08 Impact factor: 2.493
Authors: Anne E Wiktor; Daniel L Van Dyke; Peggy J Stupca; Rhett P Ketterling; Erik C Thorland; Brandon M Shearer; Stephanie R Fink; Kimberly J Stockero; Jason R Majorowicz; Gordon W Dewald Journal: Genet Med Date: 2006-01 Impact factor: 8.822
Authors: N Zojer; M Fiegl; L Müllauer; A Chott; S Roka; J Ackermann; M Raderer; H Kaufmann; A Reiner; H Huber; J Drach Journal: Br J Cancer Date: 1998-04 Impact factor: 7.640
Authors: Guy A Weiss; Michael R Rossi; Nikhil I Khushalani; Ken Lo; John F Gibbs; Anubha Bharthuar; John K Cowell; Renuka Iyer Journal: J Gastrointest Oncol Date: 2013-03